Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer

Pediatric Blood and Cancer

Volumn 47, Issue 5, 2006, Pages 572-579

  Freeman III, Burgess B ^a   Hinds, Pamela ^a   Iacono, Lisa C ^a   Razzouk, Bassem I ^a   Burghen, Elizabeth ^a   Stewart, Clinton F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Epoetin alfa; Erythropoietin; Pediatrics; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CHILDHOOD CANCER; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; OSTEOSARCOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHONDROSARCOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EPOETIN ALFA; FEMALE; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MELANOMA; OSTEOSARCOMA; PLACEBOS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33748479264     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20685     Document Type: Article

References (15)

1. Widness JA, Veng-Pedersen P, Peters C, et al. Erythropoietin pharmacokinetics in premature infants: Developmental, nonlinearity, and treatment effects. J Appl Physiol 1996;80:140-148.
2. Ohls RK, Veerman MW, Christensen RD. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution. J Pediatr 1996;128:518-523.
3. Brown MS, Jones MA, Ohls RK, et al. Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration. J Pediatr 1993;122:655-657.
4. Montini G, Zacchello G, Perfumo F, et al. Pharmacokinetics and hematologic response to subcutaneous administration of recombinant human erythropoietin in children undergoing long-term peritoneal dialysis: A multicenter study. J Pediatr 1993;122:297-302.
5. Wagner LM, Billups CA, Furman WL, et al. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: A randomized controlled trial. J Clin Oncol 2004;22:1886-1893.
6. Razzouk BI, Hockenberry M, Hinds PS, et al. A double-blind, placebo-controlled study of once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy (Abstract). J Clin Oncol 22:8527.
7. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokmetic/ Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource; 1997.
8. Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 1989;110:108-114.
9. Macdougall IC, Roberts DE, Neubert P, et al. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989;1:425-427.
10. Kindler J, Eckardt KU, Ehmer B, et al. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrology Dialysis Transplantation 1989;4:345-349.
11. Evans JH, Brocklebank JT, Bowmer CJ, et al. Pharmacokinetics of recombinant human erythropoietin in children with renal failure. Nephrology Dialysis Transplantation 1991;6:709-714.
12. Ashai NT, Paganini EP, Wilson JM. Intravenous versus subcutaneous dosing of epoetin: A review of the literature. Am J Kidney Dis 1993;22:23-31.
13. Lui SF, Chung WW, Leung CB, et al. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1990;33:47-51.
14. Porter JC, Leahey A, Polise K, et al. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized, double-blind, placebo-controlled trial. J Pediatr 1996;129:656-660.
15. Dunphy FR, Harrison BR, Dunleavy TL, et al. Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy. Cancer 1999;86:1362-1367.